What question did this study set out to answer?

This research aims to evaluate the utility of circulating tumor DNA (ctDNA) as a biomarker for relapse detection and molecular profiling in high-risk neuroblastoma patients.

April 5, 2026Cancer Research

Evaluation of Circulating Tumor DNA as a Biomarker in High-Risk Neuroblastoma

View Full Paper

Ask AI

Bookmark

This research aims to evaluate the utility of circulating tumor DNA (ctDNA) as a biomarker for relapse detection and molecular profiling in high-risk neuroblastoma patients.
Conducted a retrospective chart review of 13 high-risk neuroblastoma patients.
Sequenced plasma samples and compared ctDNA results with tumor sequencing.
Used International Neuroblastoma Response Criteria (INRC) for treatment response evaluations.
72% of ctDNA-positive samples were found prior to radiographic relapse.
Higher variant allele frequency (VAF) and tumor fraction (TF) correlated with progressive disease.
Complete response was strongly associated with ctDNA-negative samples.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective review evaluates ctDNA for relapse detection in high-risk neuroblastoma, suggesting its clinical potential.

Cite This Study

Wojciechowska et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcc0a79560c99a0a25ef https://doi.org/10.1158/1538-7445.am2026-5317

View Full Paper

Ask AI

Bookmark

Evaluation of Circulating Tumor DNA as a Biomarker in High-Risk Neuroblastoma

Key Points

Discussion

Implication

Cite This Study

Evaluation of Circulating Tumor DNA as a Biomarker in High-Risk Neuroblastoma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider